allogene
Allogene Therapeutics is seeking a Principal Scientist to lead the design and execution of cell starting material characterization studies and develop innovative cell isolation technologies. The role involves applying QbD principles, interpreting complex data, and collaborating cross‑functionally to support clinical and commercial manufacturing of CAR‑T therapies.
Headquarters
South San Francisco, California, United States
Company Size
201-500 employees
Founded
2017
Allogene is a clinical-stage biotechnology company developing off-the-shelf AlloCAR T cell therapies using multiplex gene engineering and gene-editing to create allogeneic (ready-made) CAR T candidates. The company pairs a proprietary lymphodepletion approach with scalable, state-of-the-art manufacturing to optimize safety, durability, and broader patient access. Lead programs include cemacabtagene ansegedleucel (cema‑cel) for large B‑cell lymphoma (including frontline DLBCL), ALLO‑316 for renal cell carcinoma, and ALLO‑329 for autoimmune disease, alongside a broader pipeline. Allogene’s platform strategy aims to accelerate delivery of cell therapies by removing patient-specific manufacturing constraints.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for allogene.
22% above the average for this role
Senior Scientist, Analytical Sciences
AstraZeneca
Bench Scientist
Global Channel Management
Scientist, Cell Therapy Bioscience
AstraZeneca
Senior Scientist I, Cell Therapy Discovery
AstraZeneca
Research Associate (Contractor), Cell Therapy
Obsidian Therapeutics
Senior/Principal Scientist, Analytical Cell Line Engineering and Bioassay Development
Takeda Pharmaceutical Company Limited